Matches in Wikidata for { <http://www.wikidata.org/entity/Q104684910> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q104684910 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 28ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104684910 description "article scientifique publié en 2020" @default.
- Q104684910 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104684910 description "im Dezember 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q104684910 description "scientific article published on 28 December 2020" @default.
- Q104684910 description "wetenschappelijk artikel" @default.
- Q104684910 description "наукова стаття, опублікована 28 грудня 2020" @default.
- Q104684910 name "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 name "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 name "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 type Item @default.
- Q104684910 label "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 label "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 label "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 prefLabel "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 prefLabel "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 prefLabel "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 P1433 Q104684910-74619ADD-07F2-4056-8D0B-2AB7F8E41018 @default.
- Q104684910 P1476 Q104684910-D005BF13-4080-4303-9FDE-B97A3449AE2B @default.
- Q104684910 P2093 Q104684910-70CA0B1B-4585-4F7E-8E9E-903A8F5F9A92 @default.
- Q104684910 P2093 Q104684910-AFBE193E-D624-4188-9887-E305A24875AE @default.
- Q104684910 P2093 Q104684910-D8F0549F-1C57-4564-84F2-21D8BDAABCAE @default.
- Q104684910 P2093 Q104684910-F336DAFA-CC2E-49E3-BF48-2FD87E33AD70 @default.
- Q104684910 P31 Q104684910-682A41BE-B31A-4362-9497-8F4A77B2747D @default.
- Q104684910 P356 Q104684910-BA91EEA1-BE40-4B09-B45B-818CFE55D9DB @default.
- Q104684910 P50 Q104684910-133CEE86-0A32-4136-B399-3819A2714DF1 @default.
- Q104684910 P50 Q104684910-51B86F9B-575F-4090-8767-001A222CB1FC @default.
- Q104684910 P50 Q104684910-7D76C25A-1DC0-4E26-A672-8C01C4B6E448 @default.
- Q104684910 P577 Q104684910-3F0DE46B-D111-4F84-B01E-EC7C9FCF1668 @default.
- Q104684910 P698 Q104684910-9239DFB3-69BF-435A-977C-E8D6E16404E3 @default.
- Q104684910 P356 J.PCAD.2020.12.008 @default.
- Q104684910 P698 33383060 @default.
- Q104684910 P1433 Q2635289 @default.
- Q104684910 P1476 "How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors" @default.
- Q104684910 P2093 "Carl J Lavie" @default.
- Q104684910 P2093 "International Lipid Expert Panel (ILEP)" @default.
- Q104684910 P2093 "Peter E Penson" @default.
- Q104684910 P2093 "Seyed Mohammad Nabavi" @default.
- Q104684910 P31 Q13442814 @default.
- Q104684910 P356 "10.1016/J.PCAD.2020.12.008" @default.
- Q104684910 P50 Q114432971 @default.
- Q104684910 P50 Q114448903 @default.
- Q104684910 P50 Q11765283 @default.
- Q104684910 P577 "2020-12-28T00:00:00Z" @default.
- Q104684910 P698 "33383060" @default.